4.6 Article

Conflicting roles of EGFR expression by subtypes in breast cancer

Journal

AMERICAN JOURNAL OF CANCER RESEARCH
Volume 11, Issue 10, Pages 5094-+

Publisher

E-CENTURY PUBLISHING CORP

Keywords

Breast cancer; cytolytic activity; EGFR; subtype; immune cell; tumor immune microenvironment; metastasis; survival analysis; triple negative breast cancer

Categories

Funding

  1. National Insti-tutes of Health, USA [R01CA160688, R01CA251545, R01CA250412, R37CA248-018]
  2. US Department of Defense BCRP [W81XWH-19-1-0674, W81XWH-19-1-0111]
  3. National Center for Advancing Translational Sciences of the National Institutes of Health [KL2TR001413, UL1TR001412]
  4. National Cancer Ins-titute, USA cancer center support grant [P30-CA016056]

Ask authors/readers for more resources

In ER-positive/HER2-negative breast cancer, high EGFR expression is associated with improved survival and an anti-cancer immune microenvironment; conversely, TNBC with higher EGFR expression has lower immune cell infiltration.
Epidermal growth factor receptor (EGFR) is one of the receptors that belong to the epidermal growth factor family of receptor tyrosine kinases (ErbBs). Several malignancies including breast cancer that express EGFR have poor prognosis. Our study examined the EGFR expression among 5176 breast cancer patients from GSE96058 and METABRIC cohorts and the contribution of tumor immune microenvironment in different subtypes. We found that among different breast cancer subtypes, EGFR expression in TNBC was the highest compared to other subtypes. EGFR high ER-positive/HER2-negative breast cancer had significantly higher survival compared to EGFR low ER-positive/HER2-negative breast cancer. It was also associated with high level of intratumor heterogeneity and homologous recombination defects (H RD). This group was also enriched in immune-related gene sets. On the other hand, low EGFR tumor was enriched in cell proliferation-related gene sets. However, these findings were not observed in TNBC. Interestingly, there was a greater infiltration of anti-cancer immune cells in high EGFR ER-positive/HER2-negative breast cancers, while, TNBC with higher EGFR expression had lower fraction of immune cells along with low level of cytolytic activity. Tumor cells have significantly higher EGFR expression compared to immune cells in single cell sequencing data. There was higher expression of immune checkpoint molecules in high EGFR ER-positive/HER2-negative breast cancer but lower expression in TNBC. High EGFR metastatic tumor was significantly associated with worse survival, but no association with infiltrating immune cells was observed. Our study shows that higher EGFR expression in ER-positive/HER2-negative breast cancer is associated with improved outcomes and an anti-cancer immune microenvironment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available